Rhenium-188 in the treatment of non-melanoma skin cancer.

Non-melanoma skin cancer (NMSC) is one of the most frequently diagnosed malignancies worldwide, especially among fair-skinned individuals. Basal cell carcinoma (BCC) is the predominant subtype, whereas squamous cell carcinoma (SCC) accounts for a smaller but increasing proportion of cases. The incidence of these tumors continues to rise due to aging populations, cumulative ultraviolet exposure and improved detection. Lesions are commonly located on cosmetically sensitive regions such as the face, scalp and neck, where treatment may significantly affect both function and appearance. Conventional therapeutic approaches include surgery, radiotherapy, cryotherapy and topical agents; however, these treatments may be associated with recurrence, cosmetic impairment or prolonged treatment duration. Rhenium-188 skin cancer therapy is a topical radionuclide-based treatment designed for superficial lesions. Owing to the limited tissue penetration of beta radiation, it can deliver high doses to the lesion while preserving surrounding healthy tissues. Published clinical evidence suggests high local control rates, good cosmetic outcomes and acceptable toxicity profiles. Therefore, Rhenium-188 may represent a valuable alternative for carefully selected patients with superficial NMSC.